LGL Group (NYSEAMERICAN:LGL) Releases Quarterly Earnings Results, Misses Expectations By $0.12 EPS

LGL Group (NYSEAMERICAN:LGL) announced its quarterly earnings data on Monday. The industrial products company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.12), FiscalAI reports. LGL Group had a return on equity of 1.62% and a net margin of 16.50%.The firm had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.50 million.

LGL Group Price Performance

LGL Group stock opened at $7.16 on Tuesday. The company has a market capitalization of $46.83 million, a PE ratio of 65.09 and a beta of 0.31. LGL Group has a one year low of $5.45 and a one year high of $9.74. The business has a 50 day simple moving average of $7.13 and a 200 day simple moving average of $6.59.

Hedge Funds Weigh In On LGL Group

A hedge fund recently raised its stake in LGL Group stock. Osaic Holdings Inc. raised its holdings in LGL Group, Inc. (The) (NYSEAMERICAN:LGL) by 15.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 20,250 shares of the industrial products company’s stock after purchasing an additional 2,710 shares during the quarter. Osaic Holdings Inc. owned approximately 0.38% of LGL Group worth $154,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 30.28% of the company’s stock.

Analyst Ratings Changes

Separately, Zacks Research raised LGL Group to a “hold” rating in a report on Thursday, May 7th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock has a consensus rating of “Hold”.

About LGL Group

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.